probiotics
Giovanni Marasco, University of Bologna, discusses the growing evidence that links gut microbiota dysbiosis to the pathophysiology, clinical prognosis, disease progression, and treatment response of patients with IBD.
Francisco Guarner Aguilar reviewed some of the most significant probiotic-related papers published in recent years, spanning basic research, clinical trials, and population-based studies.
Prof. Flavia Indrio reflects on the main take-home messages from the congress, which brought together 32 leading international experts in microbiota research, allergy, nutrition, gut-brain axis and lung disease.
VOS, an FDA-approved oral microbiota therapy, has been shown to reduce infection risk compared to traditional fecal transplants.
Gianfranco Grompone, Chief Scientific Officer at BioGaia GA, discusses the new evidences about oral microbiome.
Francesco Franceschi from Policlinico Universitario A. Gemelli IRCCS (Roma) focuses on bacterial translocation across a compromised intestinal barrier as a plausible pathway contributing to sepsis.
Camille Bello, Communication and Membership Manager at Pharmabiotics Research Institute, underscores the conference’s regulatory focus and PRI’s role in guiding microbiome innovations through complex approval pathways.
Celine Druart, Executive Director at Pharmabiotic Research Institute, discusses the 10th Pharmabiotics Conference in Brussels, from microbiome biomarkers and One Health to key regulatory developments shaping live biotherapeutic products.
Veronica Ojetti, gastroenterologist at San Carlo di Nancy Hospital (Italy), presents findings from a single-center pilot study assessing the effects of L. reuteri LMG P-27481 on the gut microbiota and…
Francesca Ponziani from Gemelli University Hospital (Italy) highlights how the gut microbiota can become a clinical tool for identifying and stratifying patients, clarifying pathogenic mechanisms, and opening up new therapeutic…
